India Glycols Limited Demerger Receives NCLT Approval

India Glycols Limited has received a significant nod for its proposed scheme of arrangement, with the National Company Law Tribunal (NCLT), Allahabad Bench, approving the demerger of its business verticals. The NCLT's certified true copy of the order, dated July 17, 2026, confirms the approval, paving the way for the creation of two independent entities. The scheme is effective from the Appointed Date of April 1, 2026.

Reader Takeaway: NCLT approval achieved; shareholders to receive new shares but record date pending.

What just happened

The NCLT has sanctioned the scheme of arrangement, which involves demerging India Glycols' Biopharma Undertaking into Ennature Bio Pharma Limited and its Spirits and Biofuel Undertaking into IGL Spirits Limited. The order confirms that the scheme is binding on all shareholders and creditors.

Why this matters

This NCLT approval marks a crucial step towards restructuring India Glycols Limited. The demerger aims to create separate, focused entities for each business vertical, potentially unlocking value and allowing for more targeted growth strategies. Shareholders will benefit from direct ownership in the demerged companies.

The backstory

India Glycols Limited, a diversified company, had proposed this scheme of arrangement to segregate its operations. The company operates in segments including glycols, spirits, industrial gases, and specialty chemicals, with recent expansions into biopharma and biofuels.

What changes now

Shareholders of India Glycols will be entitled to new shares in the resulting entities. For every 3 equity shares held in India Glycols, shareholders will receive 1 equity share in Ennature Bio Pharma Limited (face value Rs. 5). For every 1 equity share held in India Glycols, shareholders will receive 1 equity share in IGL Spirits Limited (face value Rs. 5). Existing shares held by India Glycols in these new companies will be cancelled.

Risks to watch

The primary point to watch is the announcement of the effective date and the record date. Until these dates are declared, the exact timeline for shareholders to receive their new entitlements remains uncertain. Shareholders must also monitor the performance of the newly demerged entities post-restructuring.

Peer comparison

Demergers are a common strategy in the Indian corporate landscape to unlock shareholder value. Companies like Reliance Industries have also undertaken similar large-scale demergers to create focused business units in sectors like retail and digital services. The success of such demergers often depends on the strategic direction and operational efficiency of the new entities.

Context metrics (time-bound)

• NCLT Order Date: July 17, 2026
• Appointed Date: April 1, 2026
• Share Entitlement for Ennature Bio Pharma: 1 share for every 3 India Glycols shares.
• Share Entitlement for IGL Spirits: 1 share for every 1 India Glycols share.

What to track next

Investors should keenly follow the announcements regarding the effective date and the record date. Information on the management and strategic plans for Ennature Bio Pharma Limited and IGL Spirits Limited will be crucial for assessing future prospects.